Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Hammond Janet MJ (Chief Development Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$6.84	2030-08-19	Common Stock (650000)		Direct

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on August 10, 2021 and in 36 equal monthly installments thereafter.